iForumRx.org
Mind Over Migraine: Can Mindfulness Improve Outcomes?

Mind Over Migraine: Can Mindfulness Improve Outcomes?

May 14, 2021

Nearly 12% of the population suffers from migraine headaches — which not only negatively impacts patients, but causes a major “headache” for the healthcare system, costing billions for treatment, evaluation, and lost productivity costs in the United States alone. Two-thirds of patients discontinue prophylactic or abortive migraine therapies due to ineffectiveness or adverse effects. Can mindfulness exercises help migraine sufferers find their “Zen”?

Guest Authors:  Denver Shipman, PharmD, BCPP and Elizabeth Cook, PharmD, AE-C, BCACP, CDCES

Guest Panelist: Rebecca Castner, PharmD, BCACP, AAHIVP

Music by Good Talk

Is Home Blood Pressure Monitoring a “Home Run” for Blood Pressure Management?

Is Home Blood Pressure Monitoring a “Home Run” for Blood Pressure Management?

April 29, 2021

Nearly 67 million people, which equates to 3 out of every 4 people, living with high blood pressure in the US remain uncontrolled, despite the clear and compelling benefits of achieving good control. Remote monitoring and self-management of BP may enable us to broadly achieve optimal BP control in most patients. Increased use of telehealth technology improves access to care, but the effects on the cost and quality of care, particularly in the context of hypertension management, have not been clearly established.

Guest Authors: Mary Taylor, PharmD and Megan Supple, PharmD, BCACP, CPP

Guest Panelist:  Joseph Saseen, PharmD, BCPS, BCACP, CLS

Music by Good Talk

Increasing the Patient-Clinician Connection: the “Presence 5 Practices”

Increasing the Patient-Clinician Connection: the “Presence 5 Practices”

April 16, 2021

Amidst scientific and technological advancements and an increasing focus on administrative tasks and metrics, meaningful connections with patients are falling by the wayside. Mindlessly using technology can be distracting and lower patient perceptions of their quality of care. How can the busy practitioner increase “presence” with patients while still meeting clinical and administrative demands?

Guest Authors: Emily Prohaska, PharmD, BCACP, BCGP and Nick Schulte, PharmD, BCPS

Music by Good Talk

FAST Take: Update on Febuxostat Cardiovascular Safety

FAST Take: Update on Febuxostat Cardiovascular Safety

April 2, 2021

We know gout is among the many comorbidities that increase the risk of cardiovascular disease (CVD). In 2018, the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial concluded that febuxostat was non-inferior to allopurinol. BUT, two of the secondary endpoints were very concerning. Febuxostat was inferior to allopurinol in terms of cardiovascular death and all-cause mortality. Many clinicians were left wondering whether febuxostat was cardiotoxic …. or conversely, perhaps allopurinol was cardioprotective. Will another cardiovascular outcome trial provide greater clarity to guide clinical practice?

Guest Authors: Sophia Dietrich, PharmD and Michael W. Nagy, PharmD, BCACP

Guest Panelist: Dawn Fuke, PharmD, BCPS

Music by Good Talk

Metformin During Pregnancy: Are the Results MiTy Enough to Change Practice?

Metformin During Pregnancy: Are the Results MiTy Enough to Change Practice?

March 19, 2021

The American Diabetes Association (ADA) currently recommends insulin as the preferred agent for the management of type 2 diabetes mellitus during pregnancy. However, metformin is routinely used as it has several advantages over insulin including the lower cost, less maternal weight gain, and less maternal hypoglycemia. The MiTy study explores the benefits and risks of a combination of metformin plus insulin. 

Guest Authors:  Hugh Quinn, PharmD and Mallory Telese, PharmD
Guest Panelists: Erin Raney, PharmD, BCPS, BC-ADM and Rebecca Stone, PharmD, BCPS, BCACP

Music by Good Talk

Can a Polypill ‘TIP’ the Scale to a One-Size-Fits All Approach?

Can a Polypill ‘TIP’ the Scale to a One-Size-Fits All Approach?

February 26, 2021

Creating an ideal therapeutic regimen is often like putting a puzzle together, with adherence being a critical piece of that puzzle. Studies, and clinical experience, show that patients are more likely to adhere to once-daily medication administration when compared to regimens that require more frequent dosing.  Given that pill burden and medication cost are an increasing problem, would our patients benefit from a simple, low-cost, one-size-fits-all approach to addressing cardiovascular risk?

Guests:  Ebony Isis Evans, PharmD, Katy Pincus, PharmD, BCPS, BCACP, and Sara Wettergreen, PharmD, BCACP

Music by Good Talk

There’s an App for That! Can Smartphone Apps Assist with Smoking Cessation?

There’s an App for That! Can Smartphone Apps Assist with Smoking Cessation?

February 12, 2021

Despite numerous anti-smoking campaigns, millions of adults continue to use traditional tobacco-cigarettes or e-cigarettes. Nearly 70% of smokers state they want to quit, however, less than 10% are successful.  Disappointingly, less than 60% of smokers report being offered any advice from healthcare professionals when trying to quit.  Smartphone applications are a new option for patients attempting to quit smoking in the digital age, but it is unclear if these apps improve quit rates.

Guest Authors:  Yue Pheng Vang, PharmD and Michelle Balli, PharmD, BCACP

Music by Good Talk

DECLARE-ing Another Victory for Dapagliflozin

DECLARE-ing Another Victory for Dapagliflozin

January 29, 2021

Until now, only two classes of medications have been definitively shown to delay the decline in renal function in patients with CKD: angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).  The sodium glucose co-transporter 2 inhibitors are increasingly prescribed to a wider and wider population of patients. And the latest data suggest they may have an important role in the treatment of chronic kidney disease (CKD) in patients with ... or without ... diabetes. 

Guest Authors:  Stefanie C. Nigro, PharmD, BCACP and Jennifer N. Clements, PharmD, BCPS, BCACP, CDCES, BC-ADM

Music by Good Talk

Closing the Loop for Children with Type 1 Diabetes

Closing the Loop for Children with Type 1 Diabetes

January 15, 2021

Insulin pumps and continuous glucose monitors (CGM) have changed the standard of care for managing Type 1 Diabetes. A closed-loop system (also described as an artificial pancreas or automated insulin delivery system) consists of a CGM, an insulin pump, and a control algorithm that automatically calculates basal insulin delivery based on real-time glucose levels. Closed-loop insulin pumps may offer an opportunity to improve glycemic management while reducing some of the associated stress. However, there are limited data evaluating the safety and efficacy of this technology in children less than 14 years old.

Guest Authors:  Mary K Culp, PharmD and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES

Music by Good Talk

Is it Time to Add Colchicine to the CVD Cocktail?

Is it Time to Add Colchicine to the CVD Cocktail?

January 4, 2021

Systemic inflammation appears to be an important contributor to atherosclerotic cardiovascular disease but, to date, no medications have been approved that specifically target systemic inflammation. Could colchicine, an anti-inflammatory drug that has been used for decades, move from “perhaps-do” to a “must-do” standard of care for patients with coronary artery disease (CAD)? Data from two previous trials have demonstrated colchicine’s positive impact on cardiovascular outcomes. The LoDoCo2 study asks us, again, to consider colchicine for patients with CAD.

Guest Authors:  Augustus (Rob) Hough, PharmD, BCCP and Taylor Huff, PharmD

Music by Good Talk

Podbean App

Play this podcast on Podbean App